TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02702544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioScreen 1000 - Haemodynamic Measurement System, Medis
Description: Impedance cardiography (ICG)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioScreen 1000 - Haemodynamic Measurement System, Medis
Description: Impedance cardiography (ICG)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioScreen 1000 - Haemodynamic Measurement System, Medis
Description: Impedance cardiography (ICG)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioScreen 1000 - Haemodynamic Measurement System, Medis
Description: Impedance cardiography (ICG)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioScreen 1000 - Haemodynamic Measurement System, Medis
Description: Impedance cardiography (ICG)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCHILLER, BR-102 plus - Ambulatory Blood Pressure Monitoring System
Description: Blood pressure monitoring every 1 min during leg elevation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCHILLER, BR-102 plus - Ambulatory Blood Pressure Monitoring System
Description: Blood pressure monitoring every 1 min during leg elevation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCHILLER, BR-102 plus - Ambulatory Blood Pressure Monitoring System
Description: Blood pressure monitoring every 1 min during leg elevation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCHILLER, BR-102 plus - Ambulatory Blood Pressure Monitoring System
Description: Blood pressure monitoring every 1 min during leg elevation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCHILLER, BR-102 plus - Ambulatory Blood Pressure Monitoring System
Description: Blood pressure monitoring every 1 min during leg elevation
Study: NCT03335176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance ad Resistance Training Exercise
Description: Patients received a 6-week tele-supervised rehabilitation with 3 exercise sessions per week
Study: NCT02249325

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic dietary supplement
Description: Florajen3 is a commercially available probiotic supplement containing three bacteria of human origin (\>7.5 x10\^9 L. acidophilus, \>6.0 x10\^9 .B. lactis, and \>1.5 x10\^9 B .longum). Once capsule was administered daily by mouth from 28 through 36 weeks gestation.
Study: NCT04382482

Intervention type: DEVICE
Intervention: Tachidino
Description: Web-platform delivering remote treatment of reading and spelling disorders through the (visual or auditory) presentation of words and sentences to be either decoded or corrected (reordering wrong letter sequences).
Study: NCT01776229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure, Relaxation, & Rescripting Therapy-Child
Description: Exposure, Relaxation, \& Rescripting Therapy (ERRT) will be conducted once a week for five consecutive weeks for approximately two hours per session. Each treatment session focuses on one of the following topics/skills: psycho-education and investment in treatment, psycho-education, Progressive Muscle Relaxation, diaphragmatic breathing,child-friendly exposure to the trauma-nightmare, and rescription.
Study: NCT01552486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic Spinal Manipulative Therapy
Description: Patients will receive a course high-velocity low-amplitude thrust spinal manipulation 3 times per week for 4 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Patients will be under the care of the their general physician and will be allowed the following medications: gabapentin, pregabalin, nortriptyline, amitriptyline.
Study: NCT02726620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamine
Description: Cardiovascular drug used to treat intraoperative hypotension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dopamine
Description: Cardiovascular drug used to treat intraoperative hypotension
Study: NCT00781950

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed
Description: 30 grams of milled flaxseed per day in food products or on its own.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Wheat and Mixed Dietary Oils
Study: NCT03250234

Intervention type: OTHER
Group type: OTHER
Intervention: Low Carbohydrate
Description: During the 3-hr recovery period after glycogen depletion participants will consume a nutrient free beverage.~For the day participants will consume a diet of 1.2 g/kg/d carbohydrate following glycogen depletion
Study: NCT04780321

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Anti-SARS-CoV-2 Monoclonal Antibody(25mg/kg;50mg/kg;100mg/kg)
Description: use dose 1/2/3 60 patients receipt JS016 intravenous infusion on day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 patients receipt placebo intravenous infusion on day 1
Study: NCT01785381

Intervention type: OTHER
Group type: OTHER
Intervention: Added value of coordinator
Description: Added value of coordinator
Study: NCT06525792

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Oxygen and standard therapy were given

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Ozone and standard therapy were given

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Best standard of care
Study: NCT05242211

Intervention type: OTHER
Group type: OTHER
Intervention: exercise test
Description: Each participants will conducted an exercise test on treadmill (using Modified Bruce Protocol) and cycle ergometer. Quark CPET metabolic cart (Cosmed, Rome, Italy) will be used to collect and analysis gas exchange. 10 minute after the graded exercise test Supra maximal exercise test (SMT) will be done for 2 minutes one stage (treadmill protocol) or 10% at cycle protocol higher than highest load achieved in the incremental test.
Study: NCT01434511

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OBI-1
Description: intravenous infusion, up to every 2-3 hours for the first 24 hours of treatment
Study: NCT01949896

Intervention type: OTHER
Group type: OTHER
Intervention: NPO
Description: Infants in this group will be made NPO for a period of time surrounding the packed red blood cell transfusion.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group: continue feedings
Description: Feedings will be continued in this group.
Study: NCT01484340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: The nicotine patch be given in three phases:~* 2 weeks of patches at enrollment~* 6 weeks of patches at two-week follow-up visit~* 2 weeks of patches at two-month follow-up visit~This schedule will cover the entire 10-week course of therapy as per label instructions: 6 weeks at 21mg; 2 weeks at 14mg; and 2 weeks at 7mg.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Counseling
Description: The advice to quit smoking message will follow NCI's 5A's model for smoking cessation counseling. This is a simple smoking cessation counseling strategy with 5 discrete components: (1) Ask about smoking at every opportunity; (2) Advise the patient to quit smoking; (3) Assess readiness to quit; (4) Assist the patient in quitting; and (5) Arrange follow-up.~Visit schedule:~* Baseline~* 2-week follow-up (Quit Day)~* 1-month follow-up~* 2-month follow-up~* 3-month follow-up~* 6-month follow-up~Participants abstinent at 6-month follow-up will be next seen at 12-month follow-up.~Participants still smoking at 6-month follow-up will be offered group-assigned intervention again.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Counseling
Description: The advice to quit smoking message will follow NCI's 5A's model for smoking cessation counseling. This is a simple smoking cessation counseling strategy with 5 discrete components: (1) Ask about smoking at every opportunity; (2) Advise the patient to quit smoking; (3) Assess readiness to quit; (4) Assist the patient in quitting; and (5) Arrange follow-up.~Visit schedule:~* Baseline~* 2-week follow-up (Quit Day)~* 1-month follow-up~* 2-month follow-up~* 3-month follow-up~* 6-month follow-up~Participants abstinent at 6-month follow-up will be next seen at 12-month follow-up.~Participants still smoking at 6-month follow-up will be offered group-assigned intervention again.
Study: NCT01060371

Intervention type: GENETIC
Intervention: All Participants
Description: If you decide to participate in this study, we will collect 1 tablespoon (15 milliliters) of blood during the first/screening visit in order to extract your DNA.

Intervention type: GENETIC
Intervention: All Participants
Description: If you decide to participate in this study, we will collect 1 tablespoon (15 milliliters) of blood during the first/screening visit in order to extract your DNA.

Intervention type: GENETIC
Intervention: All Participants
Description: If you decide to participate in this study, we will collect 1 tablespoon (15 milliliters) of blood during the first/screening visit in order to extract your DNA.

Intervention type: GENETIC
Intervention: All Participants
Description: If you decide to participate in this study, we will collect 1 tablespoon (15 milliliters) of blood during the first/screening visit in order to extract your DNA.
Study: NCT02314013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalosporin + Metronidazole
Description: intravenous antibiotics injection (3rd generation cephalosporin + metronidazole)and then change to oral antibiotics (3rd generation cephalosporin+ metronidazole) (an expected average 10 days)
Study: NCT03727282

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjust dobutamine according to the ejection volume index
Description: adjust dobutamine dose

Intervention type: PROCEDURE
Group type: OTHER
Intervention: adjust dobutamine according to the attending physician
Description: adjust dobutamine dose
Study: NCT00877968

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Whole wheat banana bread
Description: Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 62.8 g Available CHO: 51.7 g

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whole pea flour banana bread
Description: Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 67.8 g Available CHO: 52.0 g

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Whole wheat biscotti
Description: Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 79.8 g Available CHO: 53.1 g

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whole pea flour biscotti
Description: Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 86 g Available CHO: 51.7 g

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Whole wheat pasta
Description: Dose was portioned so that subjects received 50 g available carbohydrate~Portion (Dry): 70 g Available CHO: 51.1 g

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whole pea pasta
Description: Dose was portioned so that subjects received 50 g available carbohydrate Pea pasta is 30% whole pea pasta, 70 white wheat durum~Portion (Dry pasta) : 90 g Available CHO: 53.1 g

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: White bread
Description: Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 100 g Available CHO: 50 g

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Boiled yellow peas
Description: Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 100 g (dry) --\> 250 g cooked Available CHO: 52.8 g
Study: NCT03553147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SARC-F score, handgrip test and impedancemetry
Description: Participation in the study will be offered to any patient admitted to the geriatric ward, those who meet the inclusion criteria and do not have exclusion criteria will have to complete the SARC-F questionnaire during their stay, and to do the handgrip test and impedancemetry performed by a third party. Biological data (albumin, pre-albumin and C-Reactive Protein) and anthropometric data will be collected and analyzed to determine if the patient is malnourished or not, and the results of SARC-F will be compared between these 2 groups.
Study: NCT03851575

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated treatment of endocarditis
Description: For the three main bacteria species we shorten the duration of antibiotic treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual guideline therapy
Description: Usual guideline therapy
Study: NCT02435134

Intervention type: OTHER
Intervention: no intervention
Study: NCT01001182

Intervention type: OTHER
Intervention: non interventional
Description: non interventional
Study: NCT00410358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gimatecan
Study: NCT02340949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Administered I.V. at doses of 4 mg/Kg on Day 1 every 14 days. It will be supplied to sites by Sponsor as 4 ml vials at a concentration of 25 mg/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluoruracil
Description: Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluoruracil
Description: Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Once every 14 days. Day 1: 85 mg/m2 I.V. infusion in 250-500 mL, over two hours, followed by 5-FU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
Study: NCT03891225

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amniotic Membrane implantation
Description: Surgical procedure will be performed with Longemire Traverso technique. At the end of all pancreatic, biliary and duodenal anastomosis, the AM will be implanted.
Study: NCT01715285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone acetate tablets will be administered orally at a total dose of 1000 mg per day until disease progression, withdrawal of consent or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 5 mg capsule will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
Study: NCT00309959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01368289

Intervention type: PROCEDURE
Intervention: Endoscopic Mucosal Resection
Description: Endoscopic Mucosal Resection of large sessile colonic polyps.
Study: NCT02289092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check-Up
Description: Parents fill out questionnaires about their child and families and then participate in a videotaped interaction with their child. Clinicians then observe the video and analyze the questionnaires to establish family needs based on supports, stress, parenting, values, and strengths. Therapists then use this information to inform the intervention process and provide feedback to families with the use of motivational interviewing. parents identify goals for parenting and/or child behavior and to connect them with resources when needed. Feedback includes a discussion of goal attainment and plans to achieve goals. Goal achievement includes options such as (a) periodic follow-up and support, (b) brief support for change on a specific topic, and (c) community referral (e.g., substance abuse referral; domestic violence referral; referral for individual therapy for depression; referral for family therapy and support for families in conflict).
Study: NCT01715285

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Description: All participants will receive stable regimen of ADT, that is, lutenizing hormone releasing hormone (LHRH) agonists or surgical castration according to local guidelines until disease progression, withdrawal of consent or unacceptable toxicity.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Androgen deprivation therapy (ADT)
Description: All participants will receive stable regimen of ADT, that is, lutenizing hormone releasing hormone (LHRH) agonists or surgical castration according to local guidelines until disease progression, withdrawal of consent or unacceptable toxicity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abiraterone acetate Placebo
Description: Placebo matched to abiraterone acetate will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone Placebo
Description: Placebo matched to prednisone will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
Study: NCT00434434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: Aged Liquid; subcutaneous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: Lyophilized; subcutaneous repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subcutaneous repeating dose
Study: NCT03883386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: 10 mg in a capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Loratadine
Description: 10 mg in a capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered via capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered via capsule
Study: NCT06472648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioception training exercise plan with BOSU
Description: A 5' conventional warm-up (stationary cycling and active ankle mobility exercises) was performed.~Ankle proprioception training exercise plan included:~1. A 30-second series of maintaining the single-leg stance position on the BOSU with extended knee and hip holding the ball with the arms stretched out above the head~2. A series of 10 reps on the BOSU where the subject was asked to pass from the supporting-leg hip and knee starting position to a 90º knee flexion squat, keeping the ball above their heads~3. A single series of 10 reps on the BOSU where the subject started with full limb extension of the supporting member and the ball held with both hands at chest height; from this position subjects were asked to bring the free leg from 45º hip extension to 45º hip flexion~4. 10 passes between the subject and a partner where the participants started with a total extension of the supporting limb on the BOSU and the ball held in both hands in front of them.~2' rest between exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioception training exercise plan with Blackboard (BB)
Description: A 5' conventional warm-up (stationary cycling and active ankle mobility exercises) was performed.~Ankle proprioception training exercise plan included:~1. A 30-second series of maintaining the single-leg stance position on the BB with extended knee and hip holding the ball with the arms stretched out above the head~2. A series of 10 reps on the BB where the subject was asked to pass from the supporting-leg hip and knee starting position to a 90º knee flexion squat, keeping the ball above their heads~3. A single series of 10 reps on the BB where the subject started with full limb extension of the supporting member and the ball held with both hands at chest height; from this position subjects were asked to bring the free leg from 45º hip extension to 45º hip flexion~4. 10 passes between the subject and a partner where the participants started with a total extension of the supporting limb on the BB and the ball held in both hands in front of them.~2' rest between exercises.
Study: NCT02359240

Intervention type: PROCEDURE
Intervention: therapy according to SSC guidelines and muscle biopsy
Description: Septic patients will be treated according to the international guidelines for management of severe sepsis and septic shock 2012. Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing.150-300 mg muscle (wet weight) was routinely obtained , which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein

Intervention type: PROCEDURE
Intervention: standard surgery for femoral fracture and muscle biopsy
Description: Patients with femoral fracture will under standard surgery for fracture fixation. Percutaneous needle muscle biopsies will be performed. Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing.150-300 mg muscle (wet weight) was routinely obtained , which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein
Study: NCT03091439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalbavancin
Description: Participants received Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1 and on Day 8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants received an antibiotic consistent with standard of care (SOC) for osteomyelitis based on Investigator judgment. The duration of treatment was 4-6 weeks.
Study: NCT01409668

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. Amylovorus
Description: L. Amylovorus
Study: NCT02947087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolastin-C
Description: Patients will receive Prolastin-C at 60mg/kg on day 0, 7, 14, and 21 days of transplantation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive saline on day 0, 7, 14, and 21 days of transplantation
Study: NCT03141697

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon Dioxide
Description: Insufflation of Carbon Dioxide

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Room air
Description: Insufflation of room air